Literature DB >> 3759235

Development of an aerosol model of murine respiratory mycoplasmosis in mice.

J K Davis, R B Thorp, R F Parker, H White, D Dziedzic, J D'Arcy, G H Cassell.   

Abstract

Animal models of murine respiratory mycoplasmosis due to Mycoplasma pulmonis provide excellent opportunities to study respiratory disease due to an infectious agent. The purpose of the present study was to develop and characterize an aerosol model for the production of murine respiratory mycoplasmosis in mice. The exposure of mice for 30 min to aerosols generated with a DeVilbiss 45 nebulizer in a nose-only inhalation chamber consistently reproduced typical lesions. The chamber was operated with a nebulizer air flow of 5.3 liters/min at 5.0 lb/in and a diluting air flow of 20 liters/min, with the nebulizer containing 5 ml of a suspension of viable M. pulmonis organisms (a concentration between 6 X 10(5) to 6 X 10(10) CFU/ml). Infective aerosol particles of less than a 4.0-micron median aerodynamic diameter with a geometric standard deviation of approximately 2.0 reached the lungs and were evenly distributed among the different lung lobes. A minimum 1.5-log loss of viability in the M. pulmonis suspension was demonstrated. With the exception of the 50% lethal dose, all of the parameters previously established by intranasal inoculation could be examined with the aerosol model. The major advantages of the aerosol model were excellent reproducibility of exposure (both between different experiments and between animals in a given experiment), the avoidance of anesthetization, and the ability to immediately deposit the majority of the organisms in the lung. The only disadvantage was the requirement for large volumes of mycoplasmal cultures.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3759235      PMCID: PMC260136          DOI: 10.1128/iai.54.1.194-201.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Immunoprophylaxis of experimental Mycoplasma pneumoniae disease: effect of aerosol particle size and site of deposition of M. pneumoniae on the pattern of respiratory infection, disease, and immunity in hamsters.

Authors:  J V Jemski; C M Hetsko; C M Helms; M B Grizzard; J S Walker; R M Chanock
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

Review 2.  Deposition of aerosol in the respiratory tract.

Authors:  J D Brain; P A Valberg
Journal:  Am Rev Respir Dis       Date:  1979-12

3.  Mycoplasma pulmonis as the primary cause of chronic respiratory disease in rats.

Authors:  G C Jersey; C K Whitehair; G R Carter
Journal:  J Am Vet Med Assoc       Date:  1973-09-15       Impact factor: 1.936

4.  Comparison of undefined medium and its dialyzable fraction for growth of Mycoplasma.

Authors:  M E Pollock; S V Bonner
Journal:  J Bacteriol       Date:  1969-02       Impact factor: 3.490

5.  Murine respiratory mycoplasmosis in LEW and F344 rats: strain differences in lesion severity.

Authors:  J K Davis; G H Cassell
Journal:  Vet Pathol       Date:  1982-05       Impact factor: 2.221

6.  Experimental Mycoplasma pulmonis infection in pathogen-free mice. Models for studying mycoplasmosis of the respiratory tract.

Authors:  J R Lindsey; H Cassell
Journal:  Am J Pathol       Date:  1973-07       Impact factor: 4.307

7.  Multiphasic interactions of Mycoplasma pulmonis with erythrocytes defined by adherence and hemagglutination.

Authors:  F C Minion; G H Cassell; S Pnini; I Kahane
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

8.  Derrick Edward Award Lecture. The pathogenic potential of mycoplasmas: Mycoplasma pulmonis as a model.

Authors:  G H Cassell
Journal:  Rev Infect Dis       Date:  1982 May-Jun

9.  Interactions between murine alveolar macrophages and Mycoplasma pulmonis in vitro.

Authors:  J K Davis; K M Delozier; D K Asa; F C Minion; G H Cassell
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Mycoplasmal adherence with particular reference to the pathogenicity of Mycoplasma pulmonis.

Authors:  D Taylor-Robinson; P M Furr; H A Davies; R J Manchee; C Mouches; J M Bove
Journal:  Isr J Med Sci       Date:  1981-07
View more
  17 in total

1.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

2.  Fewer essential genes in mycoplasmas than previous studies suggest.

Authors:  Kevin Dybvig; Ping Lao; David S Jordan; Warren L Simmons
Journal:  FEMS Microbiol Lett       Date:  2010-08-16       Impact factor: 2.742

3.  Secretory immune responses to Mycoplasma pulmonis.

Authors:  M J Steffen; J L Ebersole
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

4.  Large-scale transposon mutagenesis of Mycoplasma pulmonis.

Authors:  Christopher T French; Ping Lao; Ann E Loraine; Brian T Matthews; Huilan Yu; Kevin Dybvig
Journal:  Mol Microbiol       Date:  2008-04-28       Impact factor: 3.501

5.  High-frequency variation in Mycoplasma pulmonis colony size.

Authors:  K Dybvig; J W Simecka; H L Watson; G H Cassell
Journal:  J Bacteriol       Date:  1989-09       Impact factor: 3.490

6.  Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis.

Authors:  James S Hagood; Priya Prabhakaran; Pallavi Kumbla; Lorena Salazar; Mark W MacEwen; Thomas H Barker; Luis A Ortiz; Trenton Schoeb; Gene P Siegal; C Bruce Alexander; Annie Pardo; Moisés Selman
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

7.  Heterogeneity among strains and a high rate of variation within strains of a major surface antigen of Mycoplasma pulmonis.

Authors:  H L Watson; L S McDaniel; D K Blalock; M T Fallon; G H Cassell
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

8.  Cytopathic effects of Mycoplasma pulmonis in vivo and in vitro.

Authors:  C T Stadtländer; H L Watson; J W Simecka; G H Cassell
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Chronic respiratory mycoplasmosis in C3H/HeN and C57BL/6N mice: lesion severity and antibody response.

Authors:  S C Cartner; J W Simecka; J R Lindsey; G H Cassell; J K Davis
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

10.  The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.

Authors:  Warren L Simmons; Kevin Dybvig
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.